Part One Disappointment For BioXcel’s Igalmi In Pivotal Agitation Trial
But Chance At Redemption Remains
Executive Summary
The US firm’s drug for schizophrenia- and bipolar-related agitation Igalmi has failed part one of a pivotal trial in at-home patients, but the option for higher dosing in part two combined with placebo-like safety could offer hope.